<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04179552</url>
  </required_header>
  <id_info>
    <org_study_id>CON-OA</org_study_id>
    <nct_id>NCT04179552</nct_id>
  </id_info>
  <brief_title>PAAG-OA Treatment for Knee Osteoarthritis</brief_title>
  <acronym>IDA</acronym>
  <official_title>Prospective, Open-label Clinical Investigation of Intra-articular Polyacrylamide Hydrogel Injection in Subjects With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Contura</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Contura</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, prospective, open-label, uncontrolled, clinical investigation&#xD;
      followed by an open-label extension clinical investigation to evaluate PAAG-OA in patients&#xD;
      with knee osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 21, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2026</completion_date>
  <primary_completion_date type="Actual">February 7, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the WOMAC pain subscale</measure>
    <time_frame>3 months</time_frame>
    <description>To evaluate the effectiveness of one injection of PAAG-OA on pain over 3 months in subjects with mild to severe knee OA. Change in WOMAC (WOMAC Osteoarthritis Index) pain subscale where a score of 0=none, and 4=extreme</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WOMAC</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>To evaluate the effectiveness of one injection of PAAG-OA on knee OA-related subject reported symptoms, function during activities of daily living. Change in WOMAC (WOMAC Osteoarthritis Index) pain subscale where a score of 0=none, and 4=extreme</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PGA</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>To evaluate the effectiveness of one injection of PAAG-OA on knee OA Patient Global Assessment (PGA). PGA is reported on a 10 cm Visual Analogue Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in WOMAC</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>To evaluate the extended effectiveness of 6 ml PAAG-OA on knee OA-related subject reported symptoms, function during activities of daily living over 6 and 12 months. Change in WOMAC (WOMAC Osteoarthritis Index) pain subscale where a score of 0=none, and 4=extreme</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PGA</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>To evaluate the extended effectiveness of 6 ml PAAG-OA on knee OA-related Patient Global Assessment (PGA) over 6 and 12 months. PGA is reported on a 10 cm Visual Analogue Scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>PAAG-OA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects receive treatment with PAAG-OA</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PAAG-OA</intervention_name>
    <description>Intra-articular injection with PAAG-OA (polyacrylamide hydrogel)</description>
    <arm_group_label>PAAG-OA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent form&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male or female, aged ≥ 18 years&#xD;
&#xD;
          4. Clinical diagnosis of knee OA according to American College of Rheumatology criteria&#xD;
&#xD;
          5. Definite radiographic OA in target knee at mild to severe stage (Kellgren-Lawrence&#xD;
             2-4)&#xD;
&#xD;
          6. Stable dose of analgesics for the past four weeks&#xD;
&#xD;
          7. Score of 2 or more (0-4 scale) on WOMAC question A1 (pain while walking on flat&#xD;
             surface)&#xD;
&#xD;
          8. Body Mass Index (BMI) &lt;35&#xD;
&#xD;
          9. For females of reproductive potential: use of adequate contraception must be used&#xD;
             throughout the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female participants who are pregnant, lactating or planning pregnancy during the&#xD;
             course of the clinical investigation&#xD;
&#xD;
          2. Previous intra-articular injection of polyacrylamide gel in the target knee&#xD;
&#xD;
          3. Previous intra-articular injection with hyaluronic acid or derivatives in target knee&#xD;
             in the previous 6 months&#xD;
&#xD;
          4. Significant valgus/varus deformity of the knee, ligamentous laxity or meniscal&#xD;
             instability&#xD;
&#xD;
          5. Diseases in target knee other than OA&#xD;
&#xD;
          6. Intra-articular injection of any substance other than hyaluronic acid (e.g.&#xD;
             corticosteroids) in the target knee within the last 3 months&#xD;
&#xD;
          7. Acute serious infection of any region that required hospital care or intravenous&#xD;
             antibiotic treatment within the last 30 days, or oral antibiotic treatment within the&#xD;
             last 14 days&#xD;
&#xD;
          8. Skin disease or infections in the area of the injection site&#xD;
&#xD;
          9. History of sepsis in any joint or any clinical concern for an infectious process in&#xD;
             the target knee&#xD;
&#xD;
         10. History of surgery in the target knee within the past 6 months&#xD;
&#xD;
         11. Symptomatic osteoarthritis of the hips, spine or ankle, that interferes with the&#xD;
             evaluation of the target knee&#xD;
&#xD;
         12. Planned surgery on any lower extremity&#xD;
&#xD;
         13. Clinically significant venous of lymphatic stasis present in the legs&#xD;
&#xD;
         14. Suffering from any unstable or severe cardio-vascular disease&#xD;
&#xD;
         15. Any other contraindication to intra-articular injection&#xD;
&#xD;
         16. Any foreign material in the target joint&#xD;
&#xD;
         17. Any significant medical condition (e.g. significant psychiatric or neurological&#xD;
             disorders or active alcohol/drug abuse) that is unstable/poorly controlled or other&#xD;
             factors that may interfere with study participation&#xD;
&#xD;
         18. Treatment with systemic steroids with daily doses equivalent of &gt;7,5 mg prednisolone&#xD;
&#xD;
         19. Significant change in physiotherapy in lower extremities related to OA within the&#xD;
             previous month&#xD;
&#xD;
         20. Fibromyalgia&#xD;
&#xD;
         21. Inflammatory or other disease/condition which may affect the knee joint (e.g.&#xD;
             rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis among others)&#xD;
&#xD;
         22. Haemophilia&#xD;
&#xD;
         23. Any other condition that in the opinion of the investigator puts a potential&#xD;
             participant at risk or otherwise precludes participation in the investigation&#xD;
&#xD;
         24. Known allergic reactions to antibiotics (azithromycin and moxifloxacin) or local&#xD;
             anaesthesia&#xD;
&#xD;
         25. Participation in any experimental device study within 6 months prior to enrolment, or&#xD;
             participation in an experimental drug study within 1 month prior to enrolment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Bliddal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Parker Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Parker Institute</name>
      <address>
        <city>Frederiksberg</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A2 Reumatologi og Idrætsmedicin</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatolog i Odense</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

